End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.785 EUR | -1.92% | +9.51% | -4.03% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.03% | 1.49M | - | ||
-18.88% | 10.91B | A- | ||
+53.75% | 3.3B | D+ | ||
-32.50% | 2.19B | C | ||
-14.31% | 2.16B | - | B- | |
-26.83% | 1.5B | C+ | ||
+28.55% | 1.09B | B- | ||
-3.28% | 737M | C+ | ||
-23.50% | 404M | C- | ||
-43.27% | 386M | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- ECX Stock
- ECX Stock
- Ratings Epigenomics AG